References
LaRusso NF, Wiesner RH, Ludwig J, et al. Primary sclerosing cholangitis. N Engl J Med 1984;310:899–903.
Wiesner RH, LaRusso NF. Climcopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200–206.
Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: A review of its clinical features, cholangiopathy, and hepatic histology. Gut 1980;21:870–877.
MacCarty RL, LaRusso NF, Wiesner RH, et al. Primary sclerosing cholangitis: Findings of cholangiography and pancreatography. Radiology 1983;149:39–44.
Snook JA, Chapman RW, Fleming K, et al. Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. Clin Exp Immunol 1989;76:30–33.
Duerr RH, Targan SR, Landers CJ, et al. A link between primary sclerosing cholangitis and ulcerative cholitis. Gastroenterology 1991;100:1385–1391.
Ludwig JH. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989;13:43–49
Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991;11:11–17
White TT, Hart MJ. Primary sclerosing cholangitis. Am J Surg 1987;153:439–443.
Shepard HA, Selby WS, Chapman RW, et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983;52:503–513.
Porayko MK, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis: A progressive disease? Semin Liver Dis 1991;11: 18–25.
Utsunomiya T. Etiology of ulcerative colitis (in Japanese). Geka (Surgery) 1992;54:13–20.
Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 1989;10:430–436.
Helzberg JH, Peterson JM, Boyer JL, Improved survival with primary sclerosing cholangitis. A review of the clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1980;79:200–206.
Warren KW, Athnassiades S, Monge JI. Primary sclerosing cholangitis. Am J Surg 1966;111:23–38.
Lefkowitch JH, Martin EC. Primary sclerosing cholangitis. A study of 42 cases. Am J Surg 1986;111:23–38.
Wiesner RH, Ludwig J, LaRusso NF, et al. Diagnosis and treatment of primary sclerosing cholangitis. Semin Liver Dis 1985;5:241–253.
Wiesner RH, Ludwig J, LaRusso NF, et al. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985;95:1395–1398.
Thorpe MEC, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis in ulcerative colitis. Gut 1967;8:435–448.
Schrumpf E, Fausa O, Kolmannskog F, et al. Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand J Gastroenterol 1982;17:33–39.
Kashihara T, Sibamoto S, Fujimori E, et al. Two cases of primary sclerosing cholangitis. Report of two cases and review of the recent literature. Gastroenterol Endosc 1990;32:1194–1204.
Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989;96:790–794.
Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21–25.
Rosen CB, Nagorney DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Disease 1991;11:26–30.
Wiesner RH, Larusso NF, Doozois RR, et al. Peristomal varices after protocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986;90:316–322.
Balasubramanian K, Wiesner RH, LaRusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 1988;95:1395–1398.
Gross JB, Ludwig J, Wiesner RH, et al. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastro enterology 1985;89:272–278.
Lichtman SN, Sartor RB. Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats. Immunol Res 1991;10:528–531.
Lichtman SN, Okoruwa EE, Keku J, et al. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992;90:1313–1322.
Ueno Y, Phillips JO, Ludwig J, et al. Nonsuppurative cholangitis induced in rodents by cholangiocyte immunization: An experimental model for immune cholangiopathies. Hepatology 1993;18:170A.
Jorge AD, Esley C, Anumada J. Family incidence of primary sclerosing cholangitis associated with immunological diseases. Endoscopy 1987;19:114–117.
Quigley EM, LaRusso NF, Ludwig J, et al. Familial occurence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983;85:1160–1165.
Chapman RW, Varghese Z, Gaul R, et al. Association of primary sclerosing cholangitis with HLA-B8, Gut 1983;24:38–41.
Schrumpf E, Fausa O, Forre O, et al. HLA antigens and immunoregulatory T cells in ulcerative colitis assciated with hepatobiliary disease. Scand J Gastroenterol 1982;17:187–191.
Sherlock S. The syndrome of disappearance bile ducts. Lancet 1987;II:493–496.
Terblanche JA, Allison HE, Nothover JMA. An ischemic basis for biliary strictures. Surgery 1983;94:52–57.
LaRusso NF, Wiesner RH, Ludwig J, et al. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036–1042.
Carry JB. Bile acids, cirrhosis and human evolution. Gastroenterology 1964;46:469–481.
Siegel JH, Barnes S, Morris JS. Bile acids in liver disease associated with inflammatory bowel disease. Digestion 1977;15: 469–481.
Dew MJ, Henegowen GP, van B Huybregts AWM, et al. Hepatotoxic effect of bile acids in inflammatory bowel disease. Gastroenterology 1980;78:1393–1401.
Holzbach RT, Marsh ME, Freedman MR, et al. Portal vein bile acids in patients with severe inflammatory bowel disease. Gut, 1980;21:428–435.
Kemeny MM, Battifora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985;202:176–181.
Kemeny N, Daly J, Erichamn B, et al. Intra-hepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459–465.
Ludwig J, Kim CH, Weisner RH, et al. Floxuridine-induced sclerosing cholangitis: An ischemic cholangiopathy? Hepatology 1989;9:215–218.
Shea WJJ, Demas BE, Goldberg HI, et al. Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: Radiographic-histologic correlation. Am J Roentgenol 1986; 146:717–721.
Minuk GY, Rascain N, Paul RW, et al. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987;5:8–13.
Rosser BG, Hay JE, Espy MJ, et al. Evidence against a pathogenic role for cytomegalovirus (CMV) in primary sclerosing cholangitis (PSC). Hepatology 1992;16:193A.
Morecki R, Glaser JH, Cho S, et al. Biliary atresia and reovirus type 3 infection. N Engl J Med 1982;307:481–484.
Bangaru B, Morecki R, Glaser JH, et al. Comparative studies of biliary atresia in the human newborn and reovirus-induced cholangitis in weanling mice. Lab Invest 1980;43:456–462.
Minuk GY, Paul RW, Lee PWK. The prevalence of antibodies to reovireas type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985;16:55–60.
Bodenheimer HCJ, LaRusso NF, Thayer WRJ, et al. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology 1983;3:150–154.
Minuk GY, Angus M, Brickman CM, et al. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985; 88:166–170.
Senaldi G, Donaldson PT, Margin S, et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 1989;97:1430–1434.
Lindor KD, Wiesner RH, Katzmann JA, et al. Lymphocyte subsets in primary sclerosing cholangitis. Dig Dis Sci 1987;32: 720–725.
Snook JA, Chapman RW, Sachdev GK, et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989;9:36–41.
Whiteside RL, Lasky S, Si L, et al. Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology 1985;5:468–474.
van de Oord JJ, Sciot R, Desmet VJ. Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol 1986;3:310–317.
Chapman RW, Kelly PM, Heryet A, et al. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988;29:422–427.
Broom U, Galumann H, Hulterantz R, et al. Distribution of HLA-DR, HLA-DP, and HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scan J Gastroenterol 1990;25:54–58.
Mayer L, Eisenhardt D, Salomon P, et al. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 1991;100:3–12.
Phillips JO, Vroman B, Ueno Y, et al. Induction of functional MHC class II protein permits redent cholangiocytes to behave as antigen presenting cells. Gastroenterology 1994;106: 961A.
Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia: A cause of chronic liver disease and biliary cirrhosis. J Hepatol 1988;7:193–199.
Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710–1717.
Porayko MK, Wiesner RH, LaRusso NF, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990;98:1594–1602.
Chapman RWG, Burroughs AK, Bass NM, et al. Long-standing asymptomatic primary sclerosing cholangitis. Report of three cases. Dig Dis Sci 1981;26:778–782.
Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology 1992;103:1893–1901.
Kaplan MM, Medical approach to primary sclerosing cholangitis. Semin Liver Dis 1991;11:56–63.
Lindor KD, LaRusso NF, Wiesner RH. Prednisone and colchicine are not of benefit after 2 years in patients with primary sclerosing cholangitis. Hepatology 1989;10:638.
Myers RN, Cooper TH, Padis N. Primary sclerosing cholangitis. Complete gross and histologic reversal after long-term steroid therapy. Am J Gastroenterol 1970;53:527–538.
Burgert SC, Brown BP, Kirkpatrick RB, et al. Positive corticosteroid response in patients with primary sclerosing cholangitis. Hepatology 1984;10:638.
Javett SL. Azathioprine in primary sclerosing cholangitis. Lancet 1971;I:810.
Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971;II:663–664.
Wiesner RH, Steiner B, LaRusso NF, et al. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology 1991;14:63A.
Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangitis and low-does oral pulse methotrexate therapy. Clinical and histologic response. Ann Intern Med 1978;106:231–235.
Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992;16:707–714.
O'Brien CB, Senior JR, Arora-Mirchandini R, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study. Hepatology 1992;14:838–847.
Van Thiel DH, Wright HI, Gavaler JS. Ursodeoxycholic acid (UDCA) therapy for primary sclerosing cholangitis (PSC): Preliminary report of a randomized controlled trial. Hepatology 1992;16:71A.
Lo SK, Herrmann R, Chapman RW, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: A double-blind placebo controlled trial. Hepatology 1992;16:92A.
May GR, Bender CE, LaRusso NF, et al. Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. Am J Radiol 1985;145:1061–1064.
Bender CE, Wiesner RH, LeRoy AJ, et al. Clinical improvement following percutaneous balloon dilatation of dominant bile duct strictures in primary sclerosing cholangitis. Gastroenterology 1992;102:A780.
Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of CA19-9 for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 1992;16:62A.
Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992;16:1290–1299.
LaRusso F, Wiesner RH. Liver and biliary diseases. Baltimore: Williams and Wilkins, 1992.
Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319–1323.
Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31–39.
Sivak MJ, Farmer RG, Lalli AF. Sclerosing cholangitis: Its increasing frequency of recognition and association with inflammatory bowel disease. J Cli Gastroenterology 1981;3:261–266.
Aadland E, Schrumpt E, Fausa O, et al. Primary sclerosing cholangitis: A long-term follow-up study. Scand J Gastroenterol 1987;22:655–664.
Stockbrügger RW, Olsson R, Jaup B, et al. Forty-six patients with primary sclerosing cholangitis. Radiological bile duct changes in relationship to clinical course and concomitant inflammatory bowel disease. Hepatogastroenterol 1988;35:289–294.
Rabinovitz M, Gavaler JS, Schade RR, et al. Does primary sclerosing cholangitis occuring in association with inflammatory bowel disease differ from that occuring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990;11:7–11.
Wiezner RH, LaRusso NF. Primary sclerosing cholangitis. In: Bouchiere I. ed. Textbook of Gastroenterology. Bailliere Tindall, London (in press)
Author information
Authors and Affiliations
Additional information
This work was supported by Grant DK24031 from the National Institutes of Health (N.F.L.) and a Senior Research Fellowship Award from the American Gastroenterological Association and the Merk Research Foundation (Y.U.)
Rights and permissions
About this article
Cite this article
Ueno, Y., LaRusso, N.F. Primary sclerosing cholangitis. J Gastroenterol 29, 531–543 (1994). https://doi.org/10.1007/BF02361256
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02361256